Altium Capital Management LP bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, Holdings Channel reports. The institutional investor bought 155,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,886,000.
Several other large investors have also recently bought and sold shares of the company. Swiss National Bank increased its holdings in shares of Xenon Pharmaceuticals by 2.4% in the first quarter. Swiss National Bank now owns 64,000 shares of the biopharmaceutical company’s stock valued at $1,146,000 after purchasing an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Xenon Pharmaceuticals by 11,115.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,505 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 6,447 shares during the period. Northern Trust Corp grew its holdings in shares of Xenon Pharmaceuticals by 8.5% in the 1st quarter. Northern Trust Corp now owns 50,562 shares of the biopharmaceutical company’s stock valued at $904,000 after buying an additional 3,940 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Xenon Pharmaceuticals by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 958,153 shares of the biopharmaceutical company’s stock valued at $17,152,000 after buying an additional 8,915 shares during the period. Finally, Elmwood Wealth Management Inc. bought a new stake in Xenon Pharmaceuticals in the 1st quarter valued at $335,000. Institutional investors own 81.51% of the company’s stock.
Shares of Xenon Pharmaceuticals stock traded up $0.65 on Thursday, reaching $32.63. 26,684 shares of the stock were exchanged, compared to its average volume of 747,656. The firm’s 50 day moving average is $19.34 and its 200-day moving average is $18.66. Xenon Pharmaceuticals Inc. has a one year low of $9.32 and a one year high of $33.72. The firm has a market cap of $1.34 billion, a PE ratio of -21.61 and a beta of 1.36.
Several equities research analysts have commented on XENE shares. Guggenheim boosted their price target on shares of Xenon Pharmaceuticals from $30.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, October 4th. TheStreet cut shares of Xenon Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Wednesday, September 22nd. Finally, Needham & Company LLC upped their target price on shares of Xenon Pharmaceuticals from $25.00 to $48.00 and gave the company a “buy” rating in a report on Monday, October 4th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $40.33.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company’s products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J.
Featured Story: Bollinger Bands
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.